Advances in adenoviral vectors: from genetic engineering to their biology

被引:136
|
作者
Yeh, P
Perricaudet, M
机构
[1] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy
[2] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy, 94805 Villejuif Cedex
来源
FASEB JOURNAL | 1997年 / 11卷 / 08期
关键词
adenovirus; viral capsid; DNA replication; gutless;
D O I
10.1096/fasebj.11.8.9240963
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ad2 and Ad5 belong to a group of human cytolytic viruses that target the respiratory airways for reproduction, whereas latent infections establish within other tissues. Signals therefore exist that control this dichotomic process in different cell types, perhaps including cis and/or trans elements of viral origin. Since 1993, Ad2- and Ad5-based adenoviruses lacking all or part of the El regulatory region have been undergoing evaluation in phase I trials that target cancer and cystic fibrosis. These viruses are extremely attenuated and actually do not reproduce in most human cells. However, they retain most of the virus genetic program and often promote a significant cytotoxicity after infection, emphasizing the need to further cripple the virus biology to extend the duration of transgene expression, if required. We will review the strategies currently followed to engineer a professional lytic virus for epithelial cells into an innocuous gene delivery vehicle. Potential effects on the transducing properties of the vector that may result from the inactivation of viral activities that normally allow/regulate extrachromosomal gene expression during wild-type infection are discussed.
引用
收藏
页码:615 / 623
页数:9
相关论文
共 50 条
  • [1] Genetic targeting of adenoviral vectors
    Krasnykh, VN
    Douglas, JT
    van Beusechem, VW
    MOLECULAR THERAPY, 2000, 1 (05) : 391 - 405
  • [2] Advances in adenoviral vectors for cancer gene therapy
    Bilbao, G
    GomezNavarro, J
    Contreras, JL
    Curiel, DT
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (12) : 1427 - 1446
  • [3] Creation of endothelial-targeted adenoviral vectors for genetic engineering of the metastatic tumor microenvironment
    Lu, Zhi Hong
    Kaliberov, Sergey
    Kaliberova, Lyudmila
    Sohn, Rebecca E.
    Du, Yingqui
    Curie, David T.
    Arbeit, Jeffrey M.
    CANCER RESEARCH, 2015, 75
  • [4] Engineering Adenoviral Vectors with Improved GBM Selectivity
    Bates, Emily A.
    Lovatt, Charlotte
    Plein, Alice R.
    Davies, James A.
    Siebzehnrubl, Florian A.
    Parker, Alan L.
    VIRUSES-BASEL, 2023, 15 (05):
  • [5] Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications
    Scarsella, Luca
    Ehrke-Schulz, Eric
    Paulussen, Michael
    Thal, Serge C.
    Ehrhardt, Anja
    Aydin, Malik
    VIRUSES-BASEL, 2024, 16 (03):
  • [6] Recent advances in genetic engineering tools based on synthetic biology
    Ren, Jun
    Lee, Jingyu
    Na, Dokyun
    JOURNAL OF MICROBIOLOGY, 2020, 58 (01) : 1 - 10
  • [7] Recent advances in genetic engineering tools based on synthetic biology
    Jun Ren
    Jingyu Lee
    Dokyun Na
    Journal of Microbiology, 2020, 58 : 1 - 10
  • [8] Genetic targeting of adenoviral vectors for systemic administration
    Smith, T
    Idamakanti, N
    Marshall-Neff, J
    Rollence, M
    Wright, P
    Mulgrew, K
    Kaleko, M
    Stevenson, SC
    MOLECULAR THERAPY, 2003, 7 (05) : S53 - S53
  • [9] Engineering adenoviral vectors for a targeted delivery of therapeutic payloads
    Hartmann, K. P.
    Van Gogh, M.
    Nagy-Davidescu, G.
    Freitag, P. C.
    Plueckthun, A.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A56 - A57
  • [10] Advances in gene transfer into haematopoietic stem cells by adenoviral vectors
    Marini, FC
    Shayakhmetov, D
    Gharwan, H
    Lieber, A
    Andreeff, M
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (08) : 847 - 856